Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

COVID-19 : Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking

SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The inflammatory phase includes therapeutic options like Tocilizumab, Anakinra, Baricitinib, Eculizumab, Emapalumab and Heparin. Human clinical trials are starting to show some results, in some cases like that of Remdesivir and corticosteroids these are controversial. Coagulopathy is a common complication in severe cases, inflammation and coagulation are intertwined and cross-talking between these two responses is known to happen. A possible amplification of this cross-talking is suggested to be implicated in the severe cases that show both a cytokine storm and coagulopathy

Year of Publication: 2020
Contained in: Virus research Vol. 286 (2020), p. 198070
All journal articles: Search for all articles in this journal
Language: English
Contributors: Magro, Giuseppe | Author
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 2494G1JF75
3QKI37EEHE
415SHH325A
4QWG6N8QKH
9005-49-6
A3ULP0F556
Baricitinib
COVID-19
Coagulation
Coronavirus
Dexamethasone
Drugs
Eculizumab
Emapalumab
I031V2H011
ISP4442I3Y
Journal Article
O3J8G9O825
OF5P57N2ZX
Remdesivir
Review
Ruxolitinib
SARS-CoV-1
SARS-CoV-2
Therapies
Tocilizumab
Treatment
baricitinib
eculizumab
lopinavir-ritonavir drug combination
remdesivir
tocilizumab
Additional Keywords: Adenosine Monophosphate
Alanine
Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Anticoagulants
Antiviral Agents
Azetidines
Betacoronavirus
Coronavirus Infections
Cytokine Release Syndrome
Disseminated Intravascular Coagulation
Drug Combinations
Heparin
Humans
Hydroxychloroquine
Inflammation
Interleukin 1 Receptor Antagonist Protein
Lopinavir
Pandemics
Pneumonia, Viral
Ritonavir
Sulfonamides
ISSN: 1872-7492
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 08.09.2020
Date Revised 08.09.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32569708
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.virusres.2020.198070
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 07178nma a2201861 c 4500
001 NLM312386044
003 DE-601
005 20200909214513.0
007 cr uuu---uuuuu
008 200623s2020 000 0 eng d
024 7 |a 10.1016/j.virusres.2020.198070  |2 doi 
028 5 2 |a pubmed20n1332.xml 
035 |a S0168-1702(20)30463-9 
035 |a (DE-599)NLM32569708 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Magro, Giuseppe 
245 1 0 |a COVID-19  |h Elektronische Ressource  |b Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking 
300 |a Online-Ressource 
500 |a Date Completed 08.09.2020 
500 |a Date Revised 08.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 Elsevier B.V. All rights reserved. 
520 |a SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The inflammatory phase includes therapeutic options like Tocilizumab, Anakinra, Baricitinib, Eculizumab, Emapalumab and Heparin. Human clinical trials are starting to show some results, in some cases like that of Remdesivir and corticosteroids these are controversial. Coagulopathy is a common complication in severe cases, inflammation and coagulation are intertwined and cross-talking between these two responses is known to happen. A possible amplification of this cross-talking is suggested to be implicated in the severe cases that show both a cytokine storm and coagulopathy 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Adenosine Monophosphate  |6 D000249  |a analogs & derivatives  |6 Q000031  |a therapeutic use  |6 Q000627 
653 2 |a Alanine  |6 D000409  |a analogs & derivatives  |6 Q000031  |a therapeutic use  |6 Q000627 
653 2 |a Anti-Inflammatory Agents  |6 D000893  |a *therapeutic use  |6 Q000627 
653 2 |a Antibodies, Monoclonal  |6 D000911  |a therapeutic use  |6 Q000627 
653 2 |a Antibodies, Monoclonal, Humanized  |6 D061067  |a therapeutic use  |6 Q000627 
653 2 |a Antibodies, Neutralizing  |6 D057134  |a therapeutic use  |6 Q000627 
653 2 |a Anticoagulants  |6 D000925  |a *therapeutic use  |6 Q000627 
653 2 |a Antiviral Agents  |6 D000998  |a *therapeutic use  |6 Q000627 
653 2 |a Azetidines  |6 D001384  |a therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640  |a *drug effects  |6 Q000187  |a immunology  |6 Q000276 
653 2 |a Coronavirus Infections  |6 D018352  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Cytokine Release Syndrome  |6 D000080424  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Disseminated Intravascular Coagulation  |6 D004211  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Drug Combinations  |6 D004338 
653 2 |a Heparin  |6 D006493  |a therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a Hydroxychloroquine  |6 D006886  |a therapeutic use  |6 Q000627 
653 2 |a Inflammation  |6 D007249 
653 2 |a Interleukin 1 Receptor Antagonist Protein  |6 D053590  |a therapeutic use  |6 Q000627 
653 2 |a Lopinavir  |6 D061466  |a therapeutic use  |6 Q000627 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Ritonavir  |6 D019438  |a therapeutic use  |6 Q000627 
653 2 |a Sulfonamides  |6 D013449  |a therapeutic use  |6 Q000627 
655 7 |a Baricitinib  |2 gnd 
655 7 |a COVID-19  |2 gnd 
655 7 |a Coagulation  |2 gnd 
655 7 |a Coronavirus  |2 gnd 
655 7 |a Dexamethasone  |2 gnd 
655 7 |a Drugs  |2 gnd 
655 7 |a Eculizumab  |2 gnd 
655 7 |a Emapalumab  |2 gnd 
655 7 |a Inflammation  |2 gnd 
655 7 |a Remdesivir  |2 gnd 
655 7 |a Ruxolitinib  |2 gnd 
655 7 |a SARS-CoV-1  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a Therapies  |2 gnd 
655 7 |a Tocilizumab  |2 gnd 
655 7 |a Treatment  |2 gnd 
655 7 |a Anti-Inflammatory Agents  |2 gnd 
655 7 |a Antibodies, Monoclonal  |2 gnd 
655 7 |a Antibodies, Monoclonal, Humanized  |2 gnd 
655 7 |a Antibodies, Neutralizing  |2 gnd 
655 7 |a Anticoagulants  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Azetidines  |2 gnd 
655 7 |a Drug Combinations  |2 gnd 
655 7 |a Emapalumab  |2 gnd 
655 7 |a Interleukin 1 Receptor Antagonist Protein  |2 gnd 
655 7 |a Sulfonamides  |2 gnd 
655 7 |a lopinavir-ritonavir drug combination  |2 gnd 
655 7 |a Lopinavir  |2 gnd 
655 7 |a 2494G1JF75  |2 gnd 
655 7 |a remdesivir  |2 gnd 
655 7 |a 3QKI37EEHE  |2 gnd 
655 7 |a Adenosine Monophosphate  |2 gnd 
655 7 |a 415SHH325A  |2 gnd 
655 7 |a Hydroxychloroquine  |2 gnd 
655 7 |a 4QWG6N8QKH  |2 gnd 
655 7 |a Heparin  |2 gnd 
655 7 |a 9005-49-6  |2 gnd 
655 7 |a eculizumab  |2 gnd 
655 7 |a A3ULP0F556  |2 gnd 
655 7 |a tocilizumab  |2 gnd 
655 7 |a I031V2H011  |2 gnd 
655 7 |a baricitinib  |2 gnd 
655 7 |a ISP4442I3Y  |2 gnd 
655 7 |a Ritonavir  |2 gnd 
655 7 |a O3J8G9O825  |2 gnd 
655 7 |a Alanine  |2 gnd 
655 7 |a OF5P57N2ZX  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Baricitinib 
689 1 1 |a COVID-19 
689 1 2 |a Coagulation 
689 1 3 |a Coronavirus 
689 1 4 |a Dexamethasone 
689 1 5 |a Drugs 
689 1 6 |a Eculizumab 
689 1 7 |a Emapalumab 
689 1 8 |a Inflammation 
689 1 9 |a Remdesivir 
689 1 X |a Ruxolitinib 
689 1 X |a SARS-CoV-1 
689 1 X |a SARS-CoV-2 
689 1 X |a Therapies 
689 1 X |a Tocilizumab 
689 1 X |a Treatment 
689 1 |5 DE-601 
689 2 0 |a Anti-Inflammatory Agents 
689 2 1 |a Antibodies, Monoclonal 
689 2 2 |a Antibodies, Monoclonal, Humanized 
689 2 3 |a Antibodies, Neutralizing 
689 2 4 |a Anticoagulants 
689 2 5 |a Antiviral Agents 
689 2 6 |a Azetidines 
689 2 7 |a Drug Combinations 
689 2 8 |a Emapalumab 
689 2 9 |a Interleukin 1 Receptor Antagonist Protein 
689 2 X |a Sulfonamides 
689 2 X |a lopinavir-ritonavir drug combination 
689 2 X |a Lopinavir 
689 2 X |A r  |a 2494G1JF75 
689 2 X |a remdesivir 
689 2 X |A r  |a 3QKI37EEHE 
689 2 X |a Adenosine Monophosphate 
689 2 X |A r  |a 415SHH325A 
689 2 X |a Hydroxychloroquine 
689 2 X |A r  |a 4QWG6N8QKH 
689 2 X |a Heparin 
689 2 X |A r  |a 9005-49-6 
689 2 X |a eculizumab 
689 2 X |A r  |a A3ULP0F556 
689 2 X |a tocilizumab 
689 2 X |A r  |a I031V2H011 
689 2 X |a baricitinib 
689 2 X |A r  |a ISP4442I3Y 
689 2 X |a Ritonavir 
689 2 X |A r  |a O3J8G9O825 
689 2 X |a Alanine 
689 2 X |A r  |a OF5P57N2ZX 
689 2 |5 DE-601 
773 0 8 |i in  |t Virus research  |g Vol. 286 (2020), p. 198070  |q 286<198070  |w (DE-601)NLM012921440  |x 1872-7492 
856 4 1 |u http://dx.doi.org/10.1016/j.virusres.2020.198070  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 286  |j 2020  |b 20  |c 09  |h 198070